Audit: QRS - Enclomiphene to Improve Testosterone
Audit conducted on 08/08/2026 18:56 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every gate item, protocol cell, tier item, marker row, and qualitative item traces to a named ER passage (ER Key Interactions & Contraindications, Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks & Side Effects, Monitoring Protocol & Defining Success, Conclusion). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Whether better numbers make men feel better is unsettled” mirrors ER line 548; “Symptomatic change, where it occurs” retains the ER hedge from line 472. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication thresholds (LH above 12 IU/L, haematocrit above 54%, AHI of 30 or more, Child-Pugh Class C, within 90 days) are carried at ER strength; no caution is upgraded or downgraded. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications and Key Interactions both come from ER Key Interactions & Contraindications; benefits from Expected Benefits; risks from Potential Risks & Side Effects; nothing is drawn from the modifying-factor sections. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, expert names, NCT identifiers, or brand names (Androxal, EnCyzix, Empower, Strive) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | The only attributive phrase, “Standard regimen used by leading practitioners”, is the ER’s own bold label at line 419. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Neutral, evidence-first register throughout, matching the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and thresholds paired with plain-language framing in At-A-Glance. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Descriptive constructions (“Escalated to 25 mg daily if…”, “The only regimen tested in the controlled trials”) rather than instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives; monitoring targets are presented as the ER’s functional ranges, not as orders. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of recommend/advise/should in the QRS body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Hormones and enzymes are written out in full (luteinizing hormone, follicle-stimulating hormone, sex hormone-binding globulin); no unexpanded acronyms. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Tier rows are single semicolon-separated lines; gate items are single clauses; marker rows are short phrases. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan for “you”/”your”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional target ranges, self-monitoring cadence, and qualitative tracking items address a proactive optimizer. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Twelve-marker panel, paired morning draws 2–10 days apart, and semen analysis assume a high-effort audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nothing is simplified toward a general-population reader; assay-level detail is retained. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Unapproved status and unverified supply quality are surfaced as a High risk, which is the audience-specific signal. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The term “anti-aging” does not appear in the QRS. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “oral medication”, “venous blood clots”, “gynecomastia”, “haematocrit” are used; the plainer terms in At-A-Glance are the ER’s own Conclusion wording and are required by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels, and column headers match the template byte-for-byte. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 22 distinct template variable names are present; the repeatable marker_#_* and qualitative_item_# spans are instantiated as marker_1–marker_12 and qualitative_item_1–qualitative_item_6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A normalized diff against the template shows the head, CSS block, footer disclaimer, and the non-variable spans (website="evidence_review", website="audit", website="full_review") are unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty; every tier, gate, and table has content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard regimen used by leading practitioners”, “Best time of day”, “Single versus split dosing” are verbatim ER bold labels (ER lines 419, 425, 429); marker names are verbatim ER table row labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Protocol and marker labels are copied unchanged; the Time-to-Effect labels are the ER’s own subject terms from the Time to effect bullet (testosterone, semen parameters, symptomatic change). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji present; the ER’s “⚠️ Conflicted” markers on two headings were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content is at the compressed limit permitted by the mandatory items: single-line tier rows, parentheticals stripped from monitoring targets, CYP3A4 example lists trimmed, and At-A-Glance at 54 words. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The comment opens at line 2, immediately after the doctype, and closes at line 14 before the template comment and <html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3 and closing --- at line 13; the descriptive text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | It sits inside an HTML comment and no element echoes its values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: enclomiphene_testosterone_2026-0808-1531_Opus_ER.md at line 4. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02, matching the version badge of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0808-1834 in the required format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus at line 7. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 at line 8. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: enclomiphene_testosterone_2026-0808-1531_Opus_QRS.html matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All eight remaining values are unquoted and untrimmed of any stray whitespace. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Enclomiphene to Improve Testosterone - Quick Reference Sheet”; no characters require entity encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Enclomiphene to Improve Testosterone”, matching ER frontmatter line 8. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0808-1834 renders as 08/08/2026. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The subline carries only the creation date, the AI4L link, and the model name; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Four sentences mapping to the four paragraphs of the ER Conclusion (mechanism and fertility, stability, unsettled symptom benefit, supply quality). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 54 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Traceable to ER lines 546 (mechanism, sperm production, steadier levels), 548 (unsettled symptom benefit), and 550 (no approved product, variable quality). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “estrogen’s brake on the brain’s hormone signals” and “testosterone gels”; no acronyms, no drug-class names, no register-heavy clinical words. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes, or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers of any kind appear in the At-A-Glance text. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items come from that section: the “Exogenous testosterone” bullet (ER line 377) and the “Populations who should avoid this intervention” bullet (ER line 395). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight populations from ER line 395 plus the absolute exogenous-testosterone antagonism are represented; nothing is omitted. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Nine discrete <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is a single noun phrase; the ER’s rationale clauses (“in whom the drug cannot work”, “given hepatic metabolism and biliary excretion”, “for whom there is no evidence base”) are all stripped, and no dash-led trailing clause remains. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Preserved: “above 12 IU/L with low testosterone”, “especially within 90 days”, “Child-Pugh Class C”, “above 54%”, “apnoea-hypopnoea index of 30 or more”, and the dosage-form list for exogenous testosterone. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section; thresholds are written out in words (“above 12 IU/L”, “above 54%”). |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Nine stop_items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map one-to-one to ER bullets at lines 379–393. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight caution-grade ER bullets are carried; the two absolute bullets (exogenous testosterone, populations who should avoid) are correctly routed to Contraindications instead. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight discrete <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “caution —”, “avoid in routine use —”, “monitor —” prefixes and all mitigation clauses are stripped; only the agent or agent class remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Drug lists are preserved for CYP2D6 inhibitors (complete), aromatase inhibitors (complete), and the additive supplements (complete); the CYP3A4 lists are trimmed to representative members rather than dropped, as the one-page budget permits. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section; all parenthetical content is plain comma-separated drug lists. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Eight caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from ER Therapeutic Protocol lines 419, 425, and 429. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose and titration, time of day, and single-versus-split dosing are the three executable decisions; the remaining bullets are comparative, contextual, or population-modifying rather than actionable. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable aspects exist and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields are populated: “12.5 mg once daily” with the escalation rule, “Morning” with the food and trough-placement note, and “Single daily dose” with the tested-regimen note. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Testosterone, sperm production, and symptoms are the three distinct clocks given in the ER Time to effect bullet at line 472. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Testosterone (High-tier benefit) first, sperm production (High-tier benefit) second, symptoms (Low-tier, conflicted benefit) last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “2 weeks” with the four-week steady state above 400 ng/dL, “3 months” with the 72–90 day spermatogenic cycle, and “Several weeks later” with the ER’s “where it occurs” hedge. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All eleven items correspond one-to-one to the eleven ER benefit headings across the four tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of the ER headings alone; none of the ER’s Magnitude: lines, confidence intervals, or caveats are carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the four benefit rows. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All fourteen items correspond one-to-one to the fourteen ER risk headings across the four tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of the ER headings alone; the ER’s incidence figures (7.1%, 4.5%, 2.2%, 0.4%) and mechanistic commentary are omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the four risk rows. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER Monitoring Protocol & Defining Success biomarker table (ER lines 500–511). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All twelve ER rows are present in ER order, with marker names, optimal functional ranges, and “Why Measure It?” text carried over. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Carries the paired baseline draws 2–10 days apart, the 4–6 week recheck and post-dose-change recheck, 3 and 6 months, every 6–12 months thereafter, and semen analysis at 3–6 months (ER lines 494 and 496). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the qualitative-marker list at ER lines 515–520. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six are present in ER order, with the ER’s trailing rationale clauses trimmed. |
Issues 08/08/2026 18:56
Pass rate 100.00%. No issues found.
Issues 08/08/2026 18:50
- 2.15 — Consumer-grade term for dosage form:
at_a_glance(line 433) says levels are “steadier than with skin gels”, while the QRS’s ownbenefits_mediumspan (line 525) uses the formal “topical testosterone” for the same comparator.
Fixes 08/08/2026 18:50
- 2.15 — Consumer-grade term for dosage form: In
at_a_glance(line 433) replaced “skin gels” with “testosterone gels”, aligning the At-A-Glance comparator with the formal register used by the QRS’s ownbenefits_mediumspan while keeping the span at 54 words.
Issues 08/08/2026 18:42
- 1.3 — Hedge dropped from time-to-effect: [time_1_sub] (line 489) states “steady state above 400 ng/dL by four weeks”, while ER line 472 hedges it as “a steady state above 400 ng/dL is typically reached by four weeks”; removing “typically” strengthens the claim.
- 4.5 — Content exceeds one A4 page: The sheet renders to roughly twice the ~1030px usable A4 height; the two gate lists (~15 and ~17 wrapped lines), the three-line protocol and time-to-effect sub-lines, and the three-line monitoring cadence are the condensable surfaces.
Fixes 08/08/2026 18:42
- 1.3 — Hedge restored in time-to-effect: [time_1_sub] changed from “steady state above 400 ng/dL by four weeks” to “steady state typically above 400 ng/dL by four weeks”, matching the ER’s own hedged wording.
- 4.5 — Protocol and time-to-effect sub-lines condensed: [action_1_sub] shortened to “Escalated to 25 mg daily if four-week morning testosterone is inadequate”, [action_2_sub] to “…in the evening, not the working day”, and [time_2_sub] to “One spermatogenic cycle is roughly 72–90 days”.
- 4.5 — Monitoring cadence condensed: Cadence rewritten from 240 to 184 characters, retaining the baseline two-draw rule, the 4–6 week, 3-month, 6-month, and 6–12 month recheck points, and the 3–6 month semen analysis.
- 4.5 — Key Interactions items trimmed: CYP3A4 and supplement-interaction example lists reduced to representative agents per the “shortened or trimmed where needed to fit the one-page budget” allowance, collapsing each item from three wrapped lines to two.